The revelation that SARS and SARS-CoV-2 uses our own ATP to aid in its own replication raises the distinct possibility that our body is creating autoantibodies against ATP/ADP. 

There is precedence for this. The features of the autoantibodies against ADP/ATP carrier from dilated CARDIOMYOPATHY and the potential role of the autoantibodies in cardiac tissue injury. The autoantibodies against ADP/ATP carrier were found with very high frequency in patients with dilated cardiomyopathy, and had disease- and organ-specificity. The autoantibodies cross-reacted with subunits of the calcium channel on the cardiac cell membrane.

The same autoantibodies are involved in ALZHEIMER'S and NEURODEGENERATION. Interestingly, in Alzheimer's they are hypothesized to interfere with cholesterol homeostasis, a feature of COVID. Furthermore, anti-ATPs-Abs, purified from AD patients, leads to poor cognitive performance and pronounced cell damage in the hippocampus, a  brain region specifically involved in learning and memory processes, which is severely affected in AD. Our results are suggestive of a role of anti-ATPs-Abs in the onset and progression of AD.